European Commission logo
English English
CORDIS - EU research results

Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification - Sofia ref.: 115881

Project description

Risk assessment for diabetes

Type 2 diabetes is a chronic metabolic disorder with an onset in adulthood. It is characterised by high blood sugar levels due to the body's ineffective use or production of the hormone insulin. There is a need to predict individuals with a risk to developing pre-diabetes by detecting insulin resistance and metabolic pathologies at an early stage. To accommodate this, the EU-funded RHAPSODY project will combine clinical information with genetic, biochemical and epigenetic data from several large cohorts of individuals with diabetes across Europe. Moreover, researchers will undertake a comparative analysis across species of the mechanisms underlying diabetes progression. The goal is to identify prognostic and diagnostic biomarkers for improved disease management.


The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, inform clinical trial design, and the establishment of regulatory paths for the adoption of novel strategies for diabetes prevention and treatment. To address these goals, RHAPSODY will bring together prominent European experts, including the leaders of the diabetes-relevant IMI1 projects to identify, validate and characterize causal biomarkers for T2D subtypes and progression. Our plans are built upon: (a) access to large European cohorts with comprehensive genetic analyses and rich longitudinal clinical and biochemical data and samples; (b) detailed multi-omic maps of key T2D-relevant tissues and organs; (c) large expertise in the development and use of novel genetic, epigenetic, biochemical and physiological experimental approaches; (d) the ability to combine existing and novel data sets through effective data federation and use of these datasets in systems biology approaches towards precision medicine; and (e) expertise in regulatory approval, health economics and patient engagement. These activities will lead to the discovery of novel biomarkers for improved T2D taxonomy, to support development of pharmaceutical activities, and for use in precision medicine to improve health in Europe and worldwide.



Net EU contribution
€ 124 681,00

See on map

Schweiz/Suisse/Svizzera Région lémanique Vaud
Activity type
Higher or Secondary Education Establishments
Total cost
€ 1 158 682,10

Participants (28)